Relmada Therapeutics Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $69.42 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Relmada Therapeutics Inc had its IPO on 2014-10-09 under the ticker symbol RLMD.
The company operates in the Healthcare sector and Biotechnology industry. Relmada Therapeutics Inc has a staff strength of 14 employees.
Shares of Relmada Therapeutics Inc opened at $2.25 at the start of the last trading session i.e. 2023-03-31.
The stocks traded within a range of $2.12 - $2.32, and closed at $2.26.
This is a +0.89% increase from the previous day's closing price.
A total volume of 339,090 shares were traded at the close of the day’s session.
In the last one week, shares of Relmada Therapeutics Inc have slipped by -2.59%.
Relmada Therapeutics Inc's Key Ratios
Relmada Therapeutics Inc has a market cap of $69.42 million, indicating a price to book ratio of 0.5736 and a price to sales ratio of 0.
In the last 12-months Relmada Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-161247824. The EBITDA ratio measures Relmada Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Relmada Therapeutics Inc’s operating margin was 0% while its return on assets stood at -53.57% with a return of equity of -90.07%.
In Q4, Relmada Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Relmada Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-5.46 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Relmada Therapeutics Inc’s profitability.
Relmada Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.5662. Its price to sales ratio in the trailing 12-months stood at 0.
Relmada Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $152.91 million
- Total Liabilities
- $12.47 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Relmada Therapeutics Inc ended 2023 with $152.91 million in total assets and $0 in total liabilities. Its intangible assets were valued at $152.91 million while shareholder equity stood at $140.44 million.
Relmada Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $12.47 million in other current liabilities, 30099.00 in common stock, $-462110935.00 in retained earnings and $0 in goodwill. Its cash balance stood at $5.40 million and cash and short-term investments were $148.32 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Relmada Therapeutics Inc’s total current assets stands at $152.87 million while long-term investments were $0 and short-term investments were $142.93 million. Its net receivables were $512432.00 compared to accounts payable of $5.26 million and inventory worth $0.
In 2023, Relmada Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Relmada Therapeutics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Relmada Therapeutics Inc stock is currently trading at $2.26 per share. It touched a 52-week high of $38.68 and a 52-week low of $38.68. Analysts tracking the stock have a 12-month average target price of $13.38.
Its 50-day moving average was $3.36 and 200-day moving average was $13.73 The short ratio stood at 7.6 indicating a short percent outstanding of 0%.
Around 760.3% of the company’s stock are held by insiders while 6521.9% are held by institutions.
Frequently Asked Questions About Relmada Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.